Materiały źródłowe

• #1 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #2 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #3 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Every pancreatic cancer patients case is unique, and its not possible to predict each persons outcome. However, population-wide studies are done to estimate the likelihood that a person diagnosed with different types of cancer, like pancreatic cancer, will survive five years. […] The currently reported five-year survival rate for pancreatic cancer is 13%. This reflects survival for all types of pancreatic cancer combined. […] Over the past decade, the five-year survival rate for pancreatic cancer increased from 7% to 13%. […] When the tumor is only in the pancreas, the five-year survival rate is 44%. […] When pancreatic cancer has spread to nearby lymph nodes outside the pancreas, the five-year survival rate is 16%. […] The five-year survival rate for distant (stage IV) pancreatic cancer is 3%.

• #4 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Every pancreatic cancer patients case is unique, and its not possible to predict each persons outcome. However, population-wide studies are done to estimate the likelihood that a person diagnosed with different types of cancer, like pancreatic cancer, will survive five years. […] The currently reported five-year survival rate for pancreatic cancer is 13%. This reflects survival for all types of pancreatic cancer combined. […] Over the past decade, the five-year survival rate for pancreatic cancer increased from 7% to 13%. […] When the tumor is only in the pancreas, the five-year survival rate is 44%. […] When pancreatic cancer has spread to nearby lymph nodes outside the pancreas, the five-year survival rate is 16%. […] The five-year survival rate for distant (stage IV) pancreatic cancer is 3%.

• #5 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #6 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Diagnosing pancreatic cancer in time for surgery can increase a patients survival by more than ten-fold. […] In fact, a study published in 2020 demonstrated that patients whose tumor is diagnosed at the earliest stage, stage IA, can have a five-year survival of over 80%. […] Pancreatic cancer patients who participate in clinical research have better outcomes. […] Patients whose disease is diagnosed in its earlier stages have better outcomes. This is due to a greater likelihood that they are eligible for surgery.

• #7 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Diagnosing pancreatic cancer in time for surgery can increase a patients survival by more than ten-fold. […] In fact, a study published in 2020 demonstrated that patients whose tumor is diagnosed at the earliest stage, stage IA, can have a five-year survival of over 80%. […] Pancreatic cancer patients who participate in clinical research have better outcomes. […] Patients whose disease is diagnosed in its earlier stages have better outcomes. This is due to a greater likelihood that they are eligible for surgery.

• #8 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Your outlook depends on the stage of the cancer when it was diagnosed. This means how big it is and whether it has spread. […] The type of cancer and grade of the cancer cells can also affect your likely survival. Grade means how abnormal the cells look under the microscope. […] Your general health and fitness also affect survival. This is because the fitter you are, the better you may be able to cope with your cancer and treatment.

• #9 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Every pancreatic cancer patients case is unique, and its not possible to predict each persons outcome. However, population-wide studies are done to estimate the likelihood that a person diagnosed with different types of cancer, like pancreatic cancer, will survive five years. […] The currently reported five-year survival rate for pancreatic cancer is 13%. This reflects survival for all types of pancreatic cancer combined. […] Over the past decade, the five-year survival rate for pancreatic cancer increased from 7% to 13%. […] When the tumor is only in the pancreas, the five-year survival rate is 44%. […] When pancreatic cancer has spread to nearby lymph nodes outside the pancreas, the five-year survival rate is 16%. […] The five-year survival rate for distant (stage IV) pancreatic cancer is 3%.

• #10 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #11 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Every pancreatic cancer patients case is unique, and its not possible to predict each persons outcome. However, population-wide studies are done to estimate the likelihood that a person diagnosed with different types of cancer, like pancreatic cancer, will survive five years. […] The currently reported five-year survival rate for pancreatic cancer is 13%. This reflects survival for all types of pancreatic cancer combined. […] Over the past decade, the five-year survival rate for pancreatic cancer increased from 7% to 13%. […] When the tumor is only in the pancreas, the five-year survival rate is 44%. […] When pancreatic cancer has spread to nearby lymph nodes outside the pancreas, the five-year survival rate is 16%. […] The five-year survival rate for distant (stage IV) pancreatic cancer is 3%.

• #12 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Every pancreatic cancer patients case is unique, and its not possible to predict each persons outcome. However, population-wide studies are done to estimate the likelihood that a person diagnosed with different types of cancer, like pancreatic cancer, will survive five years. […] The currently reported five-year survival rate for pancreatic cancer is 13%. This reflects survival for all types of pancreatic cancer combined. […] Over the past decade, the five-year survival rate for pancreatic cancer increased from 7% to 13%. […] When the tumor is only in the pancreas, the five-year survival rate is 44%. […] When pancreatic cancer has spread to nearby lymph nodes outside the pancreas, the five-year survival rate is 16%. […] The five-year survival rate for distant (stage IV) pancreatic cancer is 3%.

• #13 Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data | Scientific Reports

  https://www.nature.com/articles/s41598-020-76025-1

  Predicting the prognosis of pancreatic cancer is important because of the very low survival rates of patients with this particular cancer. […] The 5-year relative survival rates for pancreatic cancer are 34% when the cancer is only growing in the pancreas, 12% when the cancer has spread to nearby lymph nodes or tissues, and 3% when the cancer has spread to other organs or the lymph nodes. […] Pancreatic cancer has a high recurrence rate even after treatment, 83.7% (7.8 months of median disease-free survival (DFS)) of pancreatic cancer patients undergoing surgery and 87% (13.4 months of median DFS) of patients receiving adjuvant chemotherapy after surgical resection experienced cancer recurrence. […] Because the overall survival (OS) rates of patients with early tumor recurrence are significantly lower than those of patients without early tumor recurrence, it is necessary to develop novel strategies for predicting recurrence.

• #14 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Pancreatic cancer is often diagnosed at an advanced stage. Your outlook (prognosis) is better if your cancer hasn’t spread and you can have surgery to remove it. […] Survival depends on many factors. No one can tell you exactly how long you will live. […] Almost 55 out of 100 people (almost 55%) survive their cancer for 1 year or more after diagnosis. More than 25 out of 100 people (more than 25%) survive their cancer for 3 years or more after diagnosis. […] Around 50 out of 100 people (around 50%) survive their cancer for 1 year or more after diagnosis. Around 15 out of 100 people (around 15%) survive their cancer for 3 years or more after diagnosis. […] Around 10 out of 100 people (around 10%) survive their cancer for 1 year or more after diagnosis. Only 1 out of 100 people (1%) survive their cancer for 3 years or more after diagnosis.

• #15 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Pancreatic cancer is often diagnosed at an advanced stage. Your outlook (prognosis) is better if your cancer hasn’t spread and you can have surgery to remove it. […] Survival depends on many factors. No one can tell you exactly how long you will live. […] Almost 55 out of 100 people (almost 55%) survive their cancer for 1 year or more after diagnosis. More than 25 out of 100 people (more than 25%) survive their cancer for 3 years or more after diagnosis. […] Around 50 out of 100 people (around 50%) survive their cancer for 1 year or more after diagnosis. Around 15 out of 100 people (around 15%) survive their cancer for 3 years or more after diagnosis. […] Around 10 out of 100 people (around 10%) survive their cancer for 1 year or more after diagnosis. Only 1 out of 100 people (1%) survive their cancer for 3 years or more after diagnosis.

• #16 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Pancreatic cancer is often diagnosed at an advanced stage. Your outlook (prognosis) is better if your cancer hasn’t spread and you can have surgery to remove it. […] Survival depends on many factors. No one can tell you exactly how long you will live. […] Almost 55 out of 100 people (almost 55%) survive their cancer for 1 year or more after diagnosis. More than 25 out of 100 people (more than 25%) survive their cancer for 3 years or more after diagnosis. […] Around 50 out of 100 people (around 50%) survive their cancer for 1 year or more after diagnosis. Around 15 out of 100 people (around 15%) survive their cancer for 3 years or more after diagnosis. […] Around 10 out of 100 people (around 10%) survive their cancer for 1 year or more after diagnosis. Only 1 out of 100 people (1%) survive their cancer for 3 years or more after diagnosis.

• #17 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Generally for adults with pancreatic cancer in England: almost 30 out of every 100 (almost 30%) survive their cancer for 1 year or more after they are diagnosed, almost 10 out of every 100 (almost 10%) survive their cancer for 5 years or more, it is estimated that only 5 out of every 100 (5%) will survive their cancer for 10 years or more after diagnosis. […] One reason for the poor outlook for pancreatic cancer is that it is often diagnosed late. The cancer is very often quite advanced. […] Only around 10 in 100 people (around 10%) can have surgery to remove pancreatic cancer, which gives the best chance of cure. […] They generally have a better outlook than adenocarcinoma of the pancreas. […] Around 80 in 100 people (around 80%) survive for 1 year or more. […] Around 40 out of 100 people (around 40%) survive their cancer for 5 years or more after diagnosis.

• #18 Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8497168/

  Cancer early detection increases the chances of survival. Some cancer types, like pancreatic cancer, are challenging to diagnose or detect early, and the stages have a fast progression rate. […] Studies predict pancreatic ductal adenocarcinoma cancer (pdac) survival is within the limits of 41.7% at one year, 8.7% at three years, and 1.9% at five years. […] The implementation of ML algorithms can improve our understanding of cancer progression. […] Accurate predictions give pathologists information on the patient’s state, surgical treatment to be done, optimal use of resources, individualized therapy, drugs to prescribe, and better patient management. […] ML techniques classify pdac patients and learn to predict the best survival period for each patient. […] ML techniques have been used to model the progression and treatment of pdac conditions.

• #19 Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data | Scientific Reports

  https://www.nature.com/articles/s41598-020-76025-1

  Predicting the prognosis of pancreatic cancer is important because of the very low survival rates of patients with this particular cancer. […] The 5-year relative survival rates for pancreatic cancer are 34% when the cancer is only growing in the pancreas, 12% when the cancer has spread to nearby lymph nodes or tissues, and 3% when the cancer has spread to other organs or the lymph nodes. […] Pancreatic cancer has a high recurrence rate even after treatment, 83.7% (7.8 months of median disease-free survival (DFS)) of pancreatic cancer patients undergoing surgery and 87% (13.4 months of median DFS) of patients receiving adjuvant chemotherapy after surgical resection experienced cancer recurrence. […] Because the overall survival (OS) rates of patients with early tumor recurrence are significantly lower than those of patients without early tumor recurrence, it is necessary to develop novel strategies for predicting recurrence.

• #20 Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data | Scientific Reports

  https://www.nature.com/articles/s41598-020-76025-1

  Predicting the prognosis of pancreatic cancer is important because of the very low survival rates of patients with this particular cancer. […] The 5-year relative survival rates for pancreatic cancer are 34% when the cancer is only growing in the pancreas, 12% when the cancer has spread to nearby lymph nodes or tissues, and 3% when the cancer has spread to other organs or the lymph nodes. […] Pancreatic cancer has a high recurrence rate even after treatment, 83.7% (7.8 months of median disease-free survival (DFS)) of pancreatic cancer patients undergoing surgery and 87% (13.4 months of median DFS) of patients receiving adjuvant chemotherapy after surgical resection experienced cancer recurrence. […] Because the overall survival (OS) rates of patients with early tumor recurrence are significantly lower than those of patients without early tumor recurrence, it is necessary to develop novel strategies for predicting recurrence.

• #21 Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery

  https://www.mdpi.com/2227-9059/12/12/2754

  The prognosis is very poor, with a 5-year overall survival rate in PDAC cancer of approximately 10%. […] Surgery alone, however, does not cure a majority of patients; median survival is around 10 months and early tumor relapse is observed in most patients. […] Prognostic markers aimed at predicting PDAC recurrence are still an unmet need. […] More recently, adjuvant chemotherapy with modified folinic acid, fluorouracil, irinotecan and oxaliplatin (mFOLFIRINOX) has strongly improved outcomes, achieving median overall survival of 54.4 months in the mFOLFIRINOX group and about half of the patients being relapse-free after 2 years. […] In this study, we used a survival prediction model based on the attention-guided deep MIL proposed by Yao et al. to determine the prognosis of PDAC treated by surgery; we then characterized patients according to their prognostic groups using transcriptomic and genomic features. […] The estimated risk scores were then used to classify patients into low- or high-risk groups, based on the best cut-off strategy proposed by Hothorn et al. […] A high score was associated with an HR of 0.72 [0.54;0.96]; p = 0.03 for PFS and 0.70 [0.52;0.94]; and p = 0.02 for OS in the training cohort. […] In the TCGA validation set, using the same threshold, a high score was associated with an HR of 0.62 [0.42;0.94]; p = 0.01 for PFS and 0.53 [0.38;0.81]; and p = 0.001 for OS.

• #22 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Generally for adults with pancreatic cancer in England: almost 30 out of every 100 (almost 30%) survive their cancer for 1 year or more after they are diagnosed, almost 10 out of every 100 (almost 10%) survive their cancer for 5 years or more, it is estimated that only 5 out of every 100 (5%) will survive their cancer for 10 years or more after diagnosis. […] One reason for the poor outlook for pancreatic cancer is that it is often diagnosed late. The cancer is very often quite advanced. […] Only around 10 in 100 people (around 10%) can have surgery to remove pancreatic cancer, which gives the best chance of cure. […] They generally have a better outlook than adenocarcinoma of the pancreas. […] Around 80 in 100 people (around 80%) survive for 1 year or more. […] Around 40 out of 100 people (around 40%) survive their cancer for 5 years or more after diagnosis.

• #23 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #24 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #25

  https://link.springer.com/article/10.1007/s44199-023-00063-7

  Pancreatic cancer is one of the deadliest carcinogenic diseases affecting people all over the world. The majority of patients are usually detected at Stage III or Stage IV, and the chances of survival are very low once detected at the late stages. […] The three most influencing risk factors affecting the survival of pancreatic cancer patients were found to be the age of the patient, current BMI, and cigarette smoking years with contributing percentages of 35.5%, 24.3%, and 14.93%, respectively. The predictive model is approximately 96.42% accurate in predicting the survival times of the patients diagnosed with pancreatic cancer and performs excellently on test data. […] Even for the tiny proportion of patients who have a localized, resectable tumor, the prognosis remains poor, with only 20% surviving 5 years after surgery.

• #26 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #27 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #28 Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8497168/

  Cancer early detection increases the chances of survival. Some cancer types, like pancreatic cancer, are challenging to diagnose or detect early, and the stages have a fast progression rate. […] Studies predict pancreatic ductal adenocarcinoma cancer (pdac) survival is within the limits of 41.7% at one year, 8.7% at three years, and 1.9% at five years. […] The implementation of ML algorithms can improve our understanding of cancer progression. […] Accurate predictions give pathologists information on the patient’s state, surgical treatment to be done, optimal use of resources, individualized therapy, drugs to prescribe, and better patient management. […] ML techniques classify pdac patients and learn to predict the best survival period for each patient. […] ML techniques have been used to model the progression and treatment of pdac conditions.

• #29 Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8497168/

  Predictive technique models such as ML (statistical multivariate regression and deep learning (DL)) can be used for pdac survival rate prognosis. […] The techniques can detect features from complex datasets. […] ML has been implemented in cancer prognosis or overall survival prediction. […] Most of the studies proposed for the last years focused on developing predictive models using supervised ML methods to predict disease outcomes accurately. […] The overall survival rate and the pdac relapse mostly depend on the medical treatment and the quality of the diagnosis. […] The authors suggest reinforcing different DL techniques in order to come up with an efficient pdac predictive model. An end-to-end model that will use DL techniques to predict the overall survival rate of pdac patients is proposed.

• #30 Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8497168/

  Cancer early detection increases the chances of survival. Some cancer types, like pancreatic cancer, are challenging to diagnose or detect early, and the stages have a fast progression rate. […] Studies predict pancreatic ductal adenocarcinoma cancer (pdac) survival is within the limits of 41.7% at one year, 8.7% at three years, and 1.9% at five years. […] The implementation of ML algorithms can improve our understanding of cancer progression. […] Accurate predictions give pathologists information on the patient’s state, surgical treatment to be done, optimal use of resources, individualized therapy, drugs to prescribe, and better patient management. […] ML techniques classify pdac patients and learn to predict the best survival period for each patient. […] ML techniques have been used to model the progression and treatment of pdac conditions.

• #31 Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8497168/

  Predictive technique models such as ML (statistical multivariate regression and deep learning (DL)) can be used for pdac survival rate prognosis. […] The techniques can detect features from complex datasets. […] ML has been implemented in cancer prognosis or overall survival prediction. […] Most of the studies proposed for the last years focused on developing predictive models using supervised ML methods to predict disease outcomes accurately. […] The overall survival rate and the pdac relapse mostly depend on the medical treatment and the quality of the diagnosis. […] The authors suggest reinforcing different DL techniques in order to come up with an efficient pdac predictive model. An end-to-end model that will use DL techniques to predict the overall survival rate of pdac patients is proposed.

• #32 Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study and an external validation

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11532159/

  The overall survival of patients with pancreatic cancer is extremely low. We aimed to establish machine learning (ML) based model to accurately predict three-year survival and prognosis of pancreatic cancer patients. […] A total of 20,064 pancreatic cancer patients from SEER database was consecutively enrolled. We utilized eight clinical variables to establish prediction model for three-year survival. CatBoost model was selected as the best prediction model, and AUC was 0.932 [0.924, 0.939], 0.899 [0.873, 0.934] and 0.826 [0.735, 0.919] in training, internal test and external test sets, with 0.839 [0.831, 0.847] accuracy, 0.872 [0.858, 0.887] sensitivity, 0.803 [0.784, 0.825] specificity and 0.832 [0.821, 0.853] precision. […] Our ML models demonstrate excellent accuracy and reliability, offering more precise personalized prognostic prediction to pancreatic cancer patients.

• #33

  https://link.springer.com/article/10.1007/s44199-023-00063-7

  The outcome variable of our study is the survival time (in years). […] The XGBoost method performed really well and was about 96% accurate. […] The risk factors explain 96.42% of the total variation of the response. […] In cancer research, one of the most important aspects is to estimate the survival times of the patients. […] The proposed analytical model can be implemented to any future data set containing information on different risk factors relating to the subject study to obtain very good predictive performance.

• #34 Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data | Scientific Reports

  https://www.nature.com/articles/s41598-020-76025-1

  We observed that the group with mutations in the candidate genes showed significantly poorer prognosis with regard to DFS and OS than the other group. […] Subgroup G1 showed worse prognosis in terms of DFS and OS. […] The OS rate of patients in G1 was significantly lower than that of patients in G2, and similar results were observed for DFS. […] Among the prediction models, logistic regression generally showed the best performance for both DFS and OS. […] Thus, we could classify patients with a high probability of recurrence and at a high risk of poor outcomes. […] In our predictive model, we used several different types of omics data.

• #35

  https://link.springer.com/article/10.1007/s44199-023-00063-7

  Pancreatic cancer is one of the deadliest carcinogenic diseases affecting people all over the world. The majority of patients are usually detected at Stage III or Stage IV, and the chances of survival are very low once detected at the late stages. […] The three most influencing risk factors affecting the survival of pancreatic cancer patients were found to be the age of the patient, current BMI, and cigarette smoking years with contributing percentages of 35.5%, 24.3%, and 14.93%, respectively. The predictive model is approximately 96.42% accurate in predicting the survival times of the patients diagnosed with pancreatic cancer and performs excellently on test data. […] Even for the tiny proportion of patients who have a localized, resectable tumor, the prognosis remains poor, with only 20% surviving 5 years after surgery.

• #36 Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology | Scientific Reports

  https://www.nature.com/articles/s41598-024-67757-5

  Peritoneal washing cytology (CY) in patients with pancreatic cancer is mainly used for staging; however, it may also be used to evaluate the intraperitoneal status to predict a more accurate prognosis. […] Our results indicate that AI-mediated analysis of CY specimens can successfully predict the 1-year prognosis of patients with pancreatic cancer positive for CY. […] Patients predicted to survive 1 year or more by ViT showed significantly longer survivals by KaplanMeier analyses. […] The cell nuclei found to have a negative prognostic impact by ViT appeared to be neutrophils. […] The present results suggest that intraperitoneal neutrophils are a poor prognostic factor in patients with pancreatic cancer. […] Using deep learning, we were able to predict the 1-year prognosis of patients with pancreatic cancer from CY+ specimens. […] Neutrophil exudation into the peritoneal cavity may promote tumor progression and influence prognosis. Thus, intraperitoneal neutrophils may be a new therapeutic target in patients with CY+ pancreatic cancer.

• #37 Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery

  https://www.mdpi.com/2227-9059/12/12/2754

  Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery […] Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. […] We sought to generate a deep learning approach based on hematoxylin and eosin (H&E) or hematoxylin, eosin and saffron (HES) whole slides to predict patients’ outcome, compare these new entities with known molecular subtypes and question their biological significance; […] Based on the estimation of an attention-based multi-instance learning survival model, we identified two groups of patients with a distinct prognosis. There was a significant difference in progression-free survival (PFS) between these two groups in the training set (hazard ratio HR = 0.72 [0.54;0.96]; p = 0.03) and in the validation set (HR = 0.63 [0.42;0.94]; p = 0.01). […] Our study demonstrates that deep learning could be used to predict PDAC prognosis and offer assistance in better choosing adjuvant treatment.

• #38 Survival prediction in pancreatic cancer by attention-driven feature extraction on histopathology whole slide images: a multi-cohort validation – ADS

  https://ui.adsabs.harvard.edu/abs/2024SPIE12933E..08P/abstract

  Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a dismal prognosis. Despite efforts to improve therapy outcomes in PDAC, overall survival remains at 2 to 5 years following initial diagnosis. To date, there are no established predictive or prognostic biomarkers for PDAC tumors. […] The attention-driven WSI features yielded significant stratification of low and high-risk groups in both the training (p = 0.0014, Hazard Ratio (HR), 2.0 (95 % Confidence Interval (CI) 1.3 -3.1)) and the test set (p = 0.0012 HR = 2.0 (95 % CI 1.3 -2.6)). […] Following a large, multi-institutional validation, our deep-learning approach may allow for designing more precise prognostic and predictive histopathological biomarkers for PDAC tumors.

• #39 Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study and an external validation

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11532159/

  Several biomarkers for prognosis prediction in pancreatic cancer have been identified in recent years, including CA19-9, circulating tumor DNA (ctDNA), microRNAs (miRNAs), and tumor mutational burden (TMB). […] Machine learning (ML) approach, a subset of artificial intelligence, has become increasingly popular due to its ability to handle complex, non-linear relationships, particularly effective with vast datasets and loosely structured information. […] Our study was committed to firstly developing and validating predictive and prognostic models utilizing multiple ML algorithms. […] We established a GBM prognostic model to predict prognosis of pancreatic cancer patients for achieving personalized medicine.

• #40 To Predict the Prognosis and Immunological Characteristics of Pancreatic Cancer Based on Disulfide-Death Gene Death-Related lncRNA

  https://www.mdpi.com/2227-9059/13/4/924

  To Predict the Prognosis and Immunological Characteristics of Pancreatic Cancer Based on Disulfide-Death Gene Death-Related lncRNA […] Background: Disulfide-dependent cell death, known as disulfide death, plays a pivotal regulatory role in the onset and progression of various cancers including pancreatic cancer. […] The developed prognostic model based on disulfide-associated lncRNAs exhibited significant prognostic value, allowing for reliable predictions of patient outcomes in pancreatic adenocarcinoma (PAAD). […] Our findings revealed six disulfide death-associated lncRNAs with independent prognostic value, offering a crucial indicator for predicting the prognosis of pancreatic adenocarcinoma (PAAD) patients. […] The analysis of tumor immune invasion and drug sensitivity provides a novel avenue for controlling tumor invasion and metastasis as well as reducing drug tolerance.

• #41 A prognostic machine learning model for the prediction of pancreatic adenocarcinoma prognosis based on genomic expression of four cell-cycle associated hub genes – Ahmed – Annals of Pancreatic Cancer

  https://apc.amegroups.org/article/view/7222/html

  Four cell cycle-associated genes including: TPX2, KIF20A, CCNB2, and NCAPH were identified after PPI analysis and differential expression. All genes were significantly overexpressed in PAAD, and the survival analysis showed that higher expression for all genes were associated with poorer prognosis in PAAD. The ML models predicted patients prognosis with accuracy ranging between mean estimate of 6885%. […] Higher levels of expression of certain hub genes can affect prognosis of pancreatic cancer and other types of cancer either by increasing or decreasing their survival rates. […] Upon using machine learning technique characterized by high accuracy, we discovered that four hub genes regulating normal cell-cycle were over-expressed in pancreatic adenocarcinoma patients and associated with poor prognosis and overall survival.

• #42

  https://journals.lww.com/jpancreatology/fulltext/2024/09000/psca_is_a_critical_biomarker_for_predicting_the.3.aspx

  PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients. […] This study aims to find a diagnosis/therapeutic molecule that can predict the prognosis of PC with different gene background. […] First, we found PC patients who harbored KRAS and/or TP53 gene mutation have poor overall survival. […] PSCA was a biomarker of poor prognosis in PC. […] In conclusion, we suggested that PC patients harbored KRAS/TP53 gene mutation have poor overall survival. […] Using the TCGA database and the single center data of NGS testing, we found that PSCA may be a critical biomarker for predicting the prognosis of KRAS/TP53 mutant PC patients.

• #43 A prognostic machine learning model for the prediction of pancreatic adenocarcinoma prognosis based on genomic expression of four cell-cycle associated hub genes – Ahmed – Annals of Pancreatic Cancer

  https://apc.amegroups.org/article/view/7222/html

  Identification of these hub genes can greatly improve prognosis and survival of pancreatic adenocarcinoma patients by targeting them for the development of anti-mitotic therapy. […] The survival analysis of all genes showed better prognosis and higher OS in patients with low levels of gene expression: TPX2 [OS (HR) =3.24; 95% CI: 1.563.6; log rank P value 0.000001], KIF20A [OS (HR) =2.23, 95% CI: 1.453.43; log rank P value 0.0001], CCNB2 [OS (HR) =2.54, 95% CI: 1.643.94: log rank P value 0.0001], and NCAPH [OS (HR) =2.34; 95% CI: 1.53.63; log rank P value 0.0001]. […] All the ML classification models performed with great accuracy and high precision estimates in predicting the OS in PAAD patients based on mRNA expression of the identified genes, which provides a reliable prognostic tool for PAAD and imply the replicability and reproducibility of this model in PAAD. […] Our study is the first to identify genetic biomarkers associated with cell-cycle regulation in PAAD and integrate them with ML. These findings can guide the identification of these genes as prognostic signatures to aid in the development of anti-mitotic therapy targeting these hub genes.

• #44 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Pancreatic cancer is often diagnosed at an advanced stage. Your outlook (prognosis) is better if your cancer hasn’t spread and you can have surgery to remove it. […] Survival depends on many factors. No one can tell you exactly how long you will live. […] Almost 55 out of 100 people (almost 55%) survive their cancer for 1 year or more after diagnosis. More than 25 out of 100 people (more than 25%) survive their cancer for 3 years or more after diagnosis. […] Around 50 out of 100 people (around 50%) survive their cancer for 1 year or more after diagnosis. Around 15 out of 100 people (around 15%) survive their cancer for 3 years or more after diagnosis. […] Around 10 out of 100 people (around 10%) survive their cancer for 1 year or more after diagnosis. Only 1 out of 100 people (1%) survive their cancer for 3 years or more after diagnosis.

• #45 Prognosis – Hirshberg Foundation for Pancreatic Cancer Research

  https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/

  While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. […] According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 13%. The 5-year relative survival for localized pancreatic cancer is 44%. […] About 80% of patients are diagnosed after the disease has reached an advanced stage, making the disease more difficult to treat. […] Approximately 15% to 20% of pancreatic tumors are resectable; if found before metastasis, these tumors tend to show better patient survival rates. […] The larger the tumor, the less likely it is to be cured by resection. […] There is increasing evidence that the best pancreatic cancer outcomes are achieved at major medical centers with extensive experience those that perform more than 20 Whipple procedures annually.

• #46 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Every pancreatic cancer patients case is unique, and its not possible to predict each persons outcome. However, population-wide studies are done to estimate the likelihood that a person diagnosed with different types of cancer, like pancreatic cancer, will survive five years. […] The currently reported five-year survival rate for pancreatic cancer is 13%. This reflects survival for all types of pancreatic cancer combined. […] Over the past decade, the five-year survival rate for pancreatic cancer increased from 7% to 13%. […] When the tumor is only in the pancreas, the five-year survival rate is 44%. […] When pancreatic cancer has spread to nearby lymph nodes outside the pancreas, the five-year survival rate is 16%. […] The five-year survival rate for distant (stage IV) pancreatic cancer is 3%.

• #47 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Generally for adults with pancreatic cancer in England: almost 30 out of every 100 (almost 30%) survive their cancer for 1 year or more after they are diagnosed, almost 10 out of every 100 (almost 10%) survive their cancer for 5 years or more, it is estimated that only 5 out of every 100 (5%) will survive their cancer for 10 years or more after diagnosis. […] One reason for the poor outlook for pancreatic cancer is that it is often diagnosed late. The cancer is very often quite advanced. […] Only around 10 in 100 people (around 10%) can have surgery to remove pancreatic cancer, which gives the best chance of cure. […] They generally have a better outlook than adenocarcinoma of the pancreas. […] Around 80 in 100 people (around 80%) survive for 1 year or more. […] Around 40 out of 100 people (around 40%) survive their cancer for 5 years or more after diagnosis.

• #48 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Your outlook depends on the stage of the cancer when it was diagnosed. This means how big it is and whether it has spread. […] The type of cancer and grade of the cancer cells can also affect your likely survival. Grade means how abnormal the cells look under the microscope. […] Your general health and fitness also affect survival. This is because the fitter you are, the better you may be able to cope with your cancer and treatment.

• #49

  https://journals.lww.com/jpancreatology/fulltext/2024/09000/psca_is_a_critical_biomarker_for_predicting_the.3.aspx

  PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients. […] This study aims to find a diagnosis/therapeutic molecule that can predict the prognosis of PC with different gene background. […] First, we found PC patients who harbored KRAS and/or TP53 gene mutation have poor overall survival. […] PSCA was a biomarker of poor prognosis in PC. […] In conclusion, we suggested that PC patients harbored KRAS/TP53 gene mutation have poor overall survival. […] Using the TCGA database and the single center data of NGS testing, we found that PSCA may be a critical biomarker for predicting the prognosis of KRAS/TP53 mutant PC patients.

• #50 Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data | Scientific Reports

  https://www.nature.com/articles/s41598-020-76025-1

  We observed that the group with mutations in the candidate genes showed significantly poorer prognosis with regard to DFS and OS than the other group. […] Subgroup G1 showed worse prognosis in terms of DFS and OS. […] The OS rate of patients in G1 was significantly lower than that of patients in G2, and similar results were observed for DFS. […] Among the prediction models, logistic regression generally showed the best performance for both DFS and OS. […] Thus, we could classify patients with a high probability of recurrence and at a high risk of poor outcomes. […] In our predictive model, we used several different types of omics data.

• #51 Pancreatic Cancer Treatment Outcome Predicted By Genetic Test | Inside Precision Medicine

  https://www.insideprecisionmedicine.com/topics/oncology/pancreatic-cancer-treatment-outcome-predicted-by-genetic-test/

  A genetic tool developed in Japan allows clinicians to determine which patients may benefit the most from pancreatic cancer surgery to remove advanced tumors after first undergoing treatment to shrink the tumors. […] The tumor marker gene (TMG) model involves combining the patients’ genetics with that of their tumor and was able to differentiate between patients who did well after surgery and those who did not. […] The Pancreatic Cancer Action Network predicts that 67,440 Americans will be diagnosed with pancreatic cancer this year and 51,980 people are predicted to die from the disease. It is one of the deadliest cancers with 5-year survival rates ranging from 8-13% depending on the type of pancreatic cancer, mainly because it is often diagnosed at a late stage. […] Overall, people with a high score on their model had a worse outcome than those with a low score even after successful surgery. Although further testing is needed, the researchers believe the TMG model could help personalize surgical timing or avoid unnecessary surgery in high-risk patients. It could also help select which patients would most benefit from conversion surgery.

• #52 Pancreatic Cancer AssociatedCachexia: Role of the Modified Glasgow Prognostic Score in Outcome Prediction

  https://www.scitechnol.com/peer-review/pancreatic-cancer-associatedcachexia-role-of-the-modified-glasgow-prognostic-score-in-outcome-prediction-4wJQ.php?article_id=10710

  Cancer-associated-cachexia (CAC) is a ubiquitous characteristic of pancreatic cancer (PC) and 1/3 of patients die from its complications. […] Median overall survival (OS) for pre-CP was 19.1 months vs. 4.9 months in the CP (HR 1.94 95% CI 1.10-3.43 p=0.02). […] A positive mGPS at baseline was an independent predictor of worst OS (HR 2.73, 95% CI 1.12-6.66, p=0.027). […] CAC leads to worst survival and a better understanding of this syndrome in PC may improve outcomes for these patients. […] Patients without cachexia tended to live longer, with a median survival of 19.1 months, compared to a median survival of 4.9 months of those patients without cachexia. […] When survival was calculated according to mGPS score, and adjusted for covariates in multivariate analysis, it showed a significantly worse prognosis for patients with a positive mGPS, compared with patients with mGPS of 0.

• #53 Pancreatic Cancer AssociatedCachexia: Role of the Modified Glasgow Prognostic Score in Outcome Prediction

  https://www.scitechnol.com/peer-review/pancreatic-cancer-associatedcachexia-role-of-the-modified-glasgow-prognostic-score-in-outcome-prediction-4wJQ.php?article_id=10710

  Cancer-associated-cachexia (CAC) is a ubiquitous characteristic of pancreatic cancer (PC) and 1/3 of patients die from its complications. […] Median overall survival (OS) for pre-CP was 19.1 months vs. 4.9 months in the CP (HR 1.94 95% CI 1.10-3.43 p=0.02). […] A positive mGPS at baseline was an independent predictor of worst OS (HR 2.73, 95% CI 1.12-6.66, p=0.027). […] CAC leads to worst survival and a better understanding of this syndrome in PC may improve outcomes for these patients. […] Patients without cachexia tended to live longer, with a median survival of 19.1 months, compared to a median survival of 4.9 months of those patients without cachexia. […] When survival was calculated according to mGPS score, and adjusted for covariates in multivariate analysis, it showed a significantly worse prognosis for patients with a positive mGPS, compared with patients with mGPS of 0.

• #54 Pancreatic Cancer AssociatedCachexia: Role of the Modified Glasgow Prognostic Score in Outcome Prediction

  https://www.scitechnol.com/peer-review/pancreatic-cancer-associatedcachexia-role-of-the-modified-glasgow-prognostic-score-in-outcome-prediction-4wJQ.php?article_id=10710

  Cancer-associated-cachexia (CAC) is a ubiquitous characteristic of pancreatic cancer (PC) and 1/3 of patients die from its complications. […] Median overall survival (OS) for pre-CP was 19.1 months vs. 4.9 months in the CP (HR 1.94 95% CI 1.10-3.43 p=0.02). […] A positive mGPS at baseline was an independent predictor of worst OS (HR 2.73, 95% CI 1.12-6.66, p=0.027). […] CAC leads to worst survival and a better understanding of this syndrome in PC may improve outcomes for these patients. […] Patients without cachexia tended to live longer, with a median survival of 19.1 months, compared to a median survival of 4.9 months of those patients without cachexia. […] When survival was calculated according to mGPS score, and adjusted for covariates in multivariate analysis, it showed a significantly worse prognosis for patients with a positive mGPS, compared with patients with mGPS of 0.

• #55 Pancreatic Cancer AssociatedCachexia: Role of the Modified Glasgow Prognostic Score in Outcome Prediction

  https://www.scitechnol.com/peer-review/pancreatic-cancer-associatedcachexia-role-of-the-modified-glasgow-prognostic-score-in-outcome-prediction-4wJQ.php?article_id=10710

  Cancer-associated-cachexia (CAC) is a ubiquitous characteristic of pancreatic cancer (PC) and 1/3 of patients die from its complications. […] Median overall survival (OS) for pre-CP was 19.1 months vs. 4.9 months in the CP (HR 1.94 95% CI 1.10-3.43 p=0.02). […] A positive mGPS at baseline was an independent predictor of worst OS (HR 2.73, 95% CI 1.12-6.66, p=0.027). […] CAC leads to worst survival and a better understanding of this syndrome in PC may improve outcomes for these patients. […] Patients without cachexia tended to live longer, with a median survival of 19.1 months, compared to a median survival of 4.9 months of those patients without cachexia. […] When survival was calculated according to mGPS score, and adjusted for covariates in multivariate analysis, it showed a significantly worse prognosis for patients with a positive mGPS, compared with patients with mGPS of 0.

• #56 Survival for pancreatic cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival

  Your outlook depends on the stage of the cancer when it was diagnosed. This means how big it is and whether it has spread. […] The type of cancer and grade of the cancer cells can also affect your likely survival. Grade means how abnormal the cells look under the microscope. […] Your general health and fitness also affect survival. This is because the fitter you are, the better you may be able to cope with your cancer and treatment.

• #57

  https://link.springer.com/article/10.1007/s44199-023-00063-7

  Pancreatic cancer is one of the deadliest carcinogenic diseases affecting people all over the world. The majority of patients are usually detected at Stage III or Stage IV, and the chances of survival are very low once detected at the late stages. […] The three most influencing risk factors affecting the survival of pancreatic cancer patients were found to be the age of the patient, current BMI, and cigarette smoking years with contributing percentages of 35.5%, 24.3%, and 14.93%, respectively. The predictive model is approximately 96.42% accurate in predicting the survival times of the patients diagnosed with pancreatic cancer and performs excellently on test data. […] Even for the tiny proportion of patients who have a localized, resectable tumor, the prognosis remains poor, with only 20% surviving 5 years after surgery.

• #58

  https://link.springer.com/article/10.1007/s44199-023-00063-7

  Pancreatic cancer is one of the deadliest carcinogenic diseases affecting people all over the world. The majority of patients are usually detected at Stage III or Stage IV, and the chances of survival are very low once detected at the late stages. […] The three most influencing risk factors affecting the survival of pancreatic cancer patients were found to be the age of the patient, current BMI, and cigarette smoking years with contributing percentages of 35.5%, 24.3%, and 14.93%, respectively. The predictive model is approximately 96.42% accurate in predicting the survival times of the patients diagnosed with pancreatic cancer and performs excellently on test data. […] Even for the tiny proportion of patients who have a localized, resectable tumor, the prognosis remains poor, with only 20% surviving 5 years after surgery.

• #59

  https://link.springer.com/article/10.1007/s44199-023-00063-7

  Pancreatic cancer is one of the deadliest carcinogenic diseases affecting people all over the world. The majority of patients are usually detected at Stage III or Stage IV, and the chances of survival are very low once detected at the late stages. […] The three most influencing risk factors affecting the survival of pancreatic cancer patients were found to be the age of the patient, current BMI, and cigarette smoking years with contributing percentages of 35.5%, 24.3%, and 14.93%, respectively. The predictive model is approximately 96.42% accurate in predicting the survival times of the patients diagnosed with pancreatic cancer and performs excellently on test data. […] Even for the tiny proportion of patients who have a localized, resectable tumor, the prognosis remains poor, with only 20% surviving 5 years after surgery.

• #60 To Predict the Prognosis and Immunological Characteristics of Pancreatic Cancer Based on Disulfide-Death Gene Death-Related lncRNA

  https://www.mdpi.com/2227-9059/13/4/924

  Pancreatic cancer is a highly malignant tumor with a poor prognosis. […] Recent studies have suggested that adjuvant chemotherapy can enhance the prognosis of pancreatic cancer patients by improving disease-free survival and overall survival. […] Thus, finding an effective biomarker or tool to predict treatment response and prognosis has become crucial. […] In this study, we utilized TCGA to obtain transcriptome data of pancreatic cancer. […] The ultimate objective of this study was to provide guidance for prognosis analysis and the identification of drug treatment targets in pancreatic cancer by utilizing the constructed disulfide-related lncRNA prognostic model and the findings from subsequent analyses. […] The high-risk group had a significantly lower survival time compared with the low-risk group. […] This indicates that patients in the high-risk group of disulfide-related lncRNA had a poorer prognosis. […] The risk score of the disulfide-related death lncRNA composition model had a significantly better prognostic value compared with other clinical characteristics. […] These findings suggest that the disulfide-related lncRNAs have strong predictive power for patient prognosis. […] Overall, these results demonstrate that the disulfide-related lncRNAs have strong prognostic value, and the prognostic model based on these lncRNAs exhibits excellent predictive accuracy for patient outcomes.

• #61 Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery

  https://www.mdpi.com/2227-9059/12/12/2754

  The prognosis is very poor, with a 5-year overall survival rate in PDAC cancer of approximately 10%. […] Surgery alone, however, does not cure a majority of patients; median survival is around 10 months and early tumor relapse is observed in most patients. […] Prognostic markers aimed at predicting PDAC recurrence are still an unmet need. […] More recently, adjuvant chemotherapy with modified folinic acid, fluorouracil, irinotecan and oxaliplatin (mFOLFIRINOX) has strongly improved outcomes, achieving median overall survival of 54.4 months in the mFOLFIRINOX group and about half of the patients being relapse-free after 2 years. […] In this study, we used a survival prediction model based on the attention-guided deep MIL proposed by Yao et al. to determine the prognosis of PDAC treated by surgery; we then characterized patients according to their prognostic groups using transcriptomic and genomic features. […] The estimated risk scores were then used to classify patients into low- or high-risk groups, based on the best cut-off strategy proposed by Hothorn et al. […] A high score was associated with an HR of 0.72 [0.54;0.96]; p = 0.03 for PFS and 0.70 [0.52;0.94]; and p = 0.02 for OS in the training cohort. […] In the TCGA validation set, using the same threshold, a high score was associated with an HR of 0.62 [0.42;0.94]; p = 0.01 for PFS and 0.53 [0.38;0.81]; and p = 0.001 for OS.

• #62 A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222270

  A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma […] The aim of this study was to create a prognostic Bayesian network that pre-operatively makes personalized predictions of post-resection survival time of 12 months or less and also performs post-operative prognostic updating. […] This Bayesian network is currently unique in the way it utilizes PubMed and patient level data to translate the existing empirical evidence surrounding potentially resectable pancreatic cancer to make personalized prognostic predictions. […] By utilizing existing PubMed data in a unique way within a BN, prognostic predictions of 12 months or less survival time post resection of PDAC were made at the pre-operative stage of the patient journey with an AUC of 0.7 even when up to 4 data points were missing.

• #63 Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study and an external validation

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11532159/

  Several biomarkers for prognosis prediction in pancreatic cancer have been identified in recent years, including CA19-9, circulating tumor DNA (ctDNA), microRNAs (miRNAs), and tumor mutational burden (TMB). […] Machine learning (ML) approach, a subset of artificial intelligence, has become increasingly popular due to its ability to handle complex, non-linear relationships, particularly effective with vast datasets and loosely structured information. […] Our study was committed to firstly developing and validating predictive and prognostic models utilizing multiple ML algorithms. […] We established a GBM prognostic model to predict prognosis of pancreatic cancer patients for achieving personalized medicine.

• #64 Pancreatic Cancer Treatment Outcome Predicted By Genetic Test | Inside Precision Medicine

  https://www.insideprecisionmedicine.com/topics/oncology/pancreatic-cancer-treatment-outcome-predicted-by-genetic-test/

  A genetic tool developed in Japan allows clinicians to determine which patients may benefit the most from pancreatic cancer surgery to remove advanced tumors after first undergoing treatment to shrink the tumors. […] The tumor marker gene (TMG) model involves combining the patients’ genetics with that of their tumor and was able to differentiate between patients who did well after surgery and those who did not. […] The Pancreatic Cancer Action Network predicts that 67,440 Americans will be diagnosed with pancreatic cancer this year and 51,980 people are predicted to die from the disease. It is one of the deadliest cancers with 5-year survival rates ranging from 8-13% depending on the type of pancreatic cancer, mainly because it is often diagnosed at a late stage. […] Overall, people with a high score on their model had a worse outcome than those with a low score even after successful surgery. Although further testing is needed, the researchers believe the TMG model could help personalize surgical timing or avoid unnecessary surgery in high-risk patients. It could also help select which patients would most benefit from conversion surgery.

• #65 To Predict the Prognosis and Immunological Characteristics of Pancreatic Cancer Based on Disulfide-Death Gene Death-Related lncRNA

  https://www.mdpi.com/2227-9059/13/4/924

  Pancreatic cancer is a highly malignant tumor with a poor prognosis. […] Recent studies have suggested that adjuvant chemotherapy can enhance the prognosis of pancreatic cancer patients by improving disease-free survival and overall survival. […] Thus, finding an effective biomarker or tool to predict treatment response and prognosis has become crucial. […] In this study, we utilized TCGA to obtain transcriptome data of pancreatic cancer. […] The ultimate objective of this study was to provide guidance for prognosis analysis and the identification of drug treatment targets in pancreatic cancer by utilizing the constructed disulfide-related lncRNA prognostic model and the findings from subsequent analyses. […] The high-risk group had a significantly lower survival time compared with the low-risk group. […] This indicates that patients in the high-risk group of disulfide-related lncRNA had a poorer prognosis. […] The risk score of the disulfide-related death lncRNA composition model had a significantly better prognostic value compared with other clinical characteristics. […] These findings suggest that the disulfide-related lncRNAs have strong predictive power for patient prognosis. […] Overall, these results demonstrate that the disulfide-related lncRNAs have strong prognostic value, and the prognostic model based on these lncRNAs exhibits excellent predictive accuracy for patient outcomes.

• #66 Pancreatic Cancer Survival Rate – Pancreatic Cancer Action Network

  https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

  Diagnosing pancreatic cancer in time for surgery can increase a patients survival by more than ten-fold. […] In fact, a study published in 2020 demonstrated that patients whose tumor is diagnosed at the earliest stage, stage IA, can have a five-year survival of over 80%. […] Pancreatic cancer patients who participate in clinical research have better outcomes. […] Patients whose disease is diagnosed in its earlier stages have better outcomes. This is due to a greater likelihood that they are eligible for surgery.

• #67 Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8497168/

  Cancer early detection increases the chances of survival. Some cancer types, like pancreatic cancer, are challenging to diagnose or detect early, and the stages have a fast progression rate. […] Studies predict pancreatic ductal adenocarcinoma cancer (pdac) survival is within the limits of 41.7% at one year, 8.7% at three years, and 1.9% at five years. […] The implementation of ML algorithms can improve our understanding of cancer progression. […] Accurate predictions give pathologists information on the patient’s state, surgical treatment to be done, optimal use of resources, individualized therapy, drugs to prescribe, and better patient management. […] ML techniques classify pdac patients and learn to predict the best survival period for each patient. […] ML techniques have been used to model the progression and treatment of pdac conditions.

• #68 A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222270

  The BN also demonstrated its ability to perform prognostic updating at the post-operative stage of the patient journey with an AUC of 0.8, which was maintained even when greater than 6 pre-operative, and 1 post-operative, data points were missing. […] This study marks a potentially significant step towards to achieving the delivery of personalized cancer care. In the clinical setting the BN presented here has the potential to have an immediate impact on improving patient counseling and facilitating better shared decision-making by providing a mechanism to communicate and transmit the complex and data rich empirical narrative surrounding a diagnosis of potentially resectable pancreatic cancer to patients on a personalized level. […] The second area of impact of this study is in directing future research. As patient databases globally develop in complexity and mature, so too should predictive modeling become more sophisticated at integrating multiple complex databases to make individualized patient predictions and support clinical decision-making.

Zobacz więcej